Skip to main navigation Skip to search Skip to main content

Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study

  • Kelly G. Paulson
  • , Sally C.M. Lau
  • , Myung Ju Ahn
  • , Mor Moskovitz
  • , Michael Pogorzelski
  • , Simon Häfliger
  • , Amanda Parkes
  • , Yuyang Zhang
  • , Ali Hamidi
  • , Corbin G. Thompson
  • , Martin Wermke
  • Swedish Medical Center
  • New York University
  • Rabin Medical Center Israel
  • University of Duisburg-Essen
  • University of Bern
  • Amgen Incorporated
  • Technische Universität Dresden

Research output: Contribution to journal › Article › peer-review

41   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology